Develops, makes, and sells scientific instruments and analytical and diagnostic solutions for academic and government research, life-science and diagnostic companies, and industrial users.
10-K for FY2025, filed Feb 27, 2026We are a developer, manufacturer, and distributor of high-performance scientific instruments and analytical and diagnostic solutions that…View ↗
The majority of BSI BioSpin’s customers are academic and government research facilities. Other customers include pharmaceutical and…View ↗
Customers of our BSI CALID Segment include pharmaceutical, biotechnology and diagnostics companies, contract research organizations…View ↗
Many contracts require an advance deposit. Customers pay for systems and other products when they ship or are accepted; maintenance and extended warranties are paid over the contract period, and other services as performed.
10-K for FY2025, filed Feb 27, 2026
10-K for FY2025, filed Feb 27, 2026
FY2025 revenue by product or service ↗$3.4B
10-K for FY2025, filed Feb 27, 2026
$3.4B ↗| Segment | Share | Revenue | How money arrives |
|---|---|---|---|
|
Product revenue
Sold outright
10-K for FY2025, filed Feb 27, 2026 |
81%
FY2022: 83%
|
Product revenue, FY2025
$2.8B Sources
|
Sold outright |
|
Service and other revenue
Mix
10-K for FY2025, filed Feb 27, 2026 |
20%
FY2022: 17%
|
Service and other revenue, FY2025
$670.1M Sources
|
Mix |
Academic and government research facilities, life-science and diagnostic companies, and industrial and clinical users buy instruments and testing solutions. Bruker sells directly in major markets and also uses distributors and independent sales representatives in some regions.
10-K for FY2025, filed Feb 27, 2026The majority of BSI BioSpin’s customers are academic and government research facilities. Other customers include pharmaceutical and…View ↗
Customers of our BSI CALID Segment include pharmaceutical, biotechnology and diagnostics companies, contract research organizations…View ↗
We maintain direct sales forces throughout North America, Europe, China, Japan, and elsewhere in the Asia Pacific region, and in certain…View ↗
Not on paper. It lost $8.6M in FY2025, but brought in more cash than it spent: $43.3M of free cash flow.
10-Q for Q3 FY2026, filed Nov 5, 2026
−$111.8MView ↗
10-Q for Q3 FY2026, filed Nov 5, 2026
Open tableView ↗
8-K, filed Nov 5, 2026
As previously announced, effective July 1, 2026 (the “Effective Date”), Bruker Corporation (the “Company”) completed a reorganization of…View ↗
8-K, filed Nov 4, 2026
Bruker continues to expect FY26 non-GAAP EPS of $2.10 to $2.15 compared to $1.83 in FY25, an increase of 15% to 17% year-over-year. Our…View ↗
Growing. Revenue grew 42% in 4 years, from $2.4B in FY2021 to $3.4B in FY2025, about 9% a year.
Competes with JEOL, QOne Instruments, Quad, Ciqtek, Magritek, Nanalysis, Oxford Instruments, PerkinElmer, Mediso, Trifoil, MR Solutions, Danaher, Agilent, GE-Healthcare, Waters, Thermo Fisher Scientific, Shimadzu, Hitachi, Biomerieux, and Foss
10-K for FY2025, filed Feb 27, 2026The BSI BioSpin Segment competes with companies that offer magnetic resonance spectrometers, mainly JEOL, QOne Instruments, Quad, Ciqtek…View ↗
Loading...